Groww Logo
Home>IPO>Windlas Biotech Ltd.

Windlas Biotech IPO

Windlas Biotech Ltd.

₹13,440 /30 sharesMinimum Investment

IPO Details

Bidding DatesMin. InvestmentLot SizePrice Range
4 Aug ‘21 - 6 Aug ‘21₹13,44030₹448 - ₹460
Issue SizeIPO Doc
401.53Cr
RHP PDF

Subscription Rate As on 06 Aug '21, 8:00 PM

  • Retail Individual Investor
    24.27x
  • Non-Institutional Investor
    15.73x
  • Qualified Institutional Buyers
    24.40x

About Company

Windlas Biotech Ltd. is amongst the top five players in the domestic pharmaceutical formulations contract development and manufacturing organization (CDMO) industry in India in terms of revenue. With over two decades of experience in manufacturing both solid and liquid pharmaceutical dosage forms and significant experience in providing specialized capabilities, including, high potency, controlled substances, and low solubility, the company provides a comprehensive range of CDMO services ranging from product discovery, product development, licensing, and commercial manufacturing of generic products, including complex generics.
... Read More
Parent Organisation
Windlas Biotech Ltd.
Founded
2000
Managing Director
Hitesh Windlass

Strengths & Risks

  • A leading CDMO in India with a focus on the chronic therapeutic category.
  • Innovative portfolio of complex generic products supported by robust R&D capabilities.
  • Efficient and quality compliant manufacturing facilities with significant entry barriers.
  • Strong and long-term relationships with leading Indian pharmaceutical companies.
  • Consistent track record of financial performance.
  • Experienced Promoters with a strong management team.
  • Dependency on the success of its relationships with its CDMO customers, including leading Indian pharmaceutical companies and multinational companies.
  • Any failure to comply with the quality standards and technical specifications prescribed by its CDMO customers.
  • Inability to identify and understand evolving industry trends, technological advancements, customer preferences, regulatory change, and innovate new products to meet customers’ demands.
  • Continuing impact of the outbreak of the COVID-19.
  • Highly competitive market.
  • Inability to meet any contractual obligations imposed by the CDMO agreements.
  • Insufficient cash flows from its operations or inability to borrow to meet its working capital requirements.
  • Non-compliance with the applicable environmental and workers’ health and safety laws and regulations.
  • Manufacturing operations are geographically concentrated in Dehradun, Uttarakhand.
  • Dependency on third-party qualified contract research organizations to conduct clinical trials and studies of the company’s new products.
  • Reforms in the healthcare industry and the uncertainty associated with pharmaceutical pricing, reimbursement, and related matters.
  • Inability to protect its intellectual property and proprietary information.
  • Any unscheduled, unplanned, or prolonged disruption of its manufacturing operations, such as strikes and lockouts.
  • Any shortfall in the supply of its raw materials or an increase in the raw material costs, or other input costs.
  • Risks associated with rejection of supplied products, and consequential claims, and associated product liability costs due to defects in its product.

Financials

*All values are in Rs. Cr
No Graph Data To Display
ⓒ 2016-2022 Groww. All rights reserved, Built with in India
MOST POPULAR ON GROWWVERSION - 2.1.5
STOCK MARKET INDICES:  S&P BSE SENSEX |  S&P BSE 100 |  NIFTY 100 |  NIFTY 50 |  NIFTY MIDCAP 100 |  NIFTY BANK |  NIFTY NEXT 50
MUTUAL FUNDS COMPANIES:  ICICI PRUDENTIAL |  HDFC |  NIPPON INDIA |  ADITYA BIRLA SUN LIFE |  SBI |  UTI |  FRANKLIN TEMPLETON |  KOTAK MAHINDRA |  IDFC |  DSP |  AXIS |  TATA |  L&T |  SUNDARAM |  PGIM |  INVESCO |  LIC |  JM FINANCIAL |  BARODA PIONEER |  CANARA ROBECO |  HSBC |  IDBI |  INDIABULLS |  MOTILAL OSWAL |  BNP PARIBAS |  MIRAE ASSET |  PRINCIPAL |  BOI AXA |  UNION KBC |  TAURUS |  EDELWEISS |  NAVI |  MAHINDRA |  QUANTUM |  PPFAS |  IIFL |  Quant |  SHRIRAM |  SAHARA |  ITI
ABOUT GROWW